Reports
Sale
Sarcopenia Market Size, Share, Trends, Analysis, Growth: By Treatment Type: Protein Supplement, Vitamin B12 Supplement, Vitamin D & Calcium Supplement, Pharmacotherapy, Others; By Route of Administration: Oral, Parenteral, Others; By End User: Hospitals, Others; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Sarcopenia Market Outlook
The sarcopenia market size is expected to grow at a CAGR of 4.3% during the forecast period of 2024-2032. The market is driven by the growing geriatric population and the increased research activities to mitigate the impact of sarcopenia on aging patients across the 8 major markets.
Sarcopenia Market Overview
Sarcopenia is characterized by a progressive decline in muscle strength and mass. Muscle weakness is a common symptom of this age-related condition. A sedentary lifestyle and unhealthy eating habits can put an individual at a higher risk of the disease. The prevalence of sarcopenia is estimated to be 10-16% among the geriatric population. The condition was reported to affect 18% of diabetic patients and 66% of patients with unresectable esophageal cancer. The increasing geriatric population base, prone to developed this skeletal muscle disorder is expected to fuel the demand for effective treatment driving sarcopenia market growth in the forecast period.
In July 2023 , a biotechnology company headquartered in France, Biophytis BSA, filed for the United States Food and Drug Administration (FDA) approval for SARA-31, the first Phase III study targeting sarcopenia. SARA-31 will evaluate Sarconeos' (BIO101) effectiveness and safety in treating sarcopenic patients prone to mobility issues. Sarconeos (an orally administered small molecule) has shown promise in Phase IIb trials. The Phase III study aims to enrol around 900 patients aged over 65 with severe sarcopenia, low walking speed, and grip strength. The development of such innovative treatment approaches to address the growing cases of sarcopenia is projected to propel the sarcopenia market demand.
The market is witnessing steady growth which can be attributed to factors such as the growing investment in research and development projects and increasing demand for pharmacological interventions aimed at enhancing muscle mass and function.
Sarcopenia Market Trends
| Key Trends | Description |
| Increased Recognition and Diagnosis | Sarcopenia is increasingly recognized as a distinct condition. This has led to improved diagnostic criteria and screening tools to identify and manage it early. |
| Nutritional Interventions | There is an increased focus on nutritional strategies, particularly protein supplementation and vitamin D, to treat or manage sarcopenia. Such interventions reflect the critical role of diet in muscle health. |
| Physical Activity and Exercise Programs using Wearable Technologies | The development of wearable technology and mobile applications to monitor the physical activity of sarcopenia patients can help improve patient outcomes. |
| Pharmacological Developments | Ongoing research into pharmacological treatments, such as anabolic agents and selective androgen receptor modulators (SARMs), aimed at directly enhancing muscle mass and function, are expected to influence the market landscape. |
Sarcopenia Market Segmentation
Market Breakup by Treatment Type
- Protein Supplement
- Vitamin B12 Supplement
- Vitamin D & Calcium Supplement
- Pharmacotherapy
- Others
The market segmentation by treatment type includes protein supplements, vitamin B12 supplements, vitamin D & calcium supplements, pharmacotherapy, and others. Protein supplements help promote muscle protein synthesis and counteract muscle loss in sarcopenia patients. Vitamin B12 supplements help address deficiencies often observed in older adults. Vitamin D & calcium supplements address potential deficiencies associated with sarcopenia by supporting bone health and muscle function. Pharmacotherapy involves medications targeting muscle mass and function to treat sarcopenia.
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Based on the route of administration, the sarcopenia market share includes oral, parenteral, and others. In oral administration, medications are taken via mouth. On the other hand, parenteral administration involves injections or infusions.
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Major end users of the market include hospitals, homecare, specialty clinics, and others. They offer specialized expertise and care for sarcopenia patients.
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online pharmacy
- Others
The distribution channels in the sarcopenia market constitute hospital pharmacies, retail pharmacies, online pharmacies, and others. To ensure accessibility and availability of sarcopenia treatments, this segment offers various channels to cater to the diverse needs of the patients.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- China
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and China. North America dominates the regional market, attributed to the presence of key market players and a robust healthcare system. Rapid technological advancements and the growth of the elderly population in the region further bolster the market growth.
Sarcopenia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Amgen Inc.
- F-Hoffmann La-Roche
- American Way (Amway) Corporation
- Abbott laboratories, Inc.
- AbbVie Inc.
- Merck Sharp & Dohme Corp.
- AstaReal AB
- Pfizer Inc.
- Sanofi S.A.
- Nestle Health Science
- Zydus Cadila
- Bayer AG
- Amgen Inc.
- Johnson & Johnson
- Novartis AG
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Sarcopenia Market Report
- How has the sarcopenia market performed so far and how will it perform in the coming years?
- What are the major market trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- What will be the effect of each driver, challenge, and opportunity on the market?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience rapid growth during the forecast period?
- What is incidence and prevalence of the condition?
- How does the prevalence and incidence of sarcopenia affect the market landscape?
- How does the rise in geriatric population impact the sarcopenia market size?
- What treatment type of sarcopenia will dominate the market share?
- What are the prominent diagnostic methods and tools used in the detection and monitoring of sarcopenia?
- How will the ongoing clinical trials impact the market value during the forecast period?
- What are the factors driving regional disparities in sarcopenia treatment and outcomes?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Sarcopenia Market Overview – 8 Major Markets
3.1 Sarcopenia Market Historical Value (2017-2023)
3.2 Sarcopenia Market Forecast Value (2024-2032)
4 Sarcopenia Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Sarcopenia Epidemiology Scenario and Forecast – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Sarcopenia Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Sarcopenia Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Sarcopenia Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Sarcopenia Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Sarcopenia Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Sarcopenia Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Sarcopenia Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Sarcopenia Epidemiology Scenario and Forecast (2017-2032)
6.5 China Sarcopenia Epidemiology Scenario and Forecast (2017-2032)
7 Sarcopenia Market Landscape – 8 Major Markets
7.1 Sarcopenia: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Sarcopenia: Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
8 Sarcopenia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Sarcopenia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Sarcopenia Market Segmentation (2017-2032) - 8 Major Markets
11.1 Sarcopenia Market (2017-2032) by Treatment Type
11.1.1 Market Overview
11.1.2 Protein Supplement
11.1.3 Vitamin B12 Supplement
11.1.4 Vitamin D & Calcium Supplement
11.1.5 Pharmacotherapy
11.1.6 Others
11.2 Sarcopenia Market (2017-2032) by Route of Administration
11.2.1 Market Overview
11.2.2 Oral
11.2.3 Parenteral
11.2.4 Others
11.3 Sarcopenia Market (2017-2032) by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Homecare
11.3.4 Specialty Clinics
11.3.5 Others
11.4 Sarcopenia Market (2017-2032) by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacy
11.4.3 Retail Pharmacy
11.4.4 Online pharmacy
11.4.5 Others
11.5 Sarcopenia Market (2017-2032) by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
11.5.5 China
12 United States Sarcopenia Market (2017-2032)
12.1 United States Sarcopenia Market Historical Value (2017-2023)
12.2 United States Sarcopenia Market Forecast Value (2024-2032)
12.3 United States Sarcopenia Market (2017-2032) by Treatment Type
12.3.1 Market Overview
12.3.2 Protein Supplement
12.3.3 Vitamin B12 Supplement
12.3.4 Vitamin D & Calcium Supplement
12.3.5 Pharmacotherapy
12.3.6 Others
12.4 United States Sarcopenia Market (2017-2032) by Route of Administration
12.4.1 Market Overview
12.4.2 Oral
12.4.3 Parenteral
12.4.4 Others
13 EU-4 and United Kingdom Sarcopenia Market (2017-2032)
13.1 EU-4 and United Kingdom Sarcopenia Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Sarcopenia Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Sarcopenia Market (2017-2032) by Treatment Type
13.3.1 Market Overview
13.3.2 Protein Supplement
13.3.3 Vitamin B12 Supplement
13.3.4 Vitamin D & Calcium Supplement
13.3.5 Pharmacotherapy
13.3.6 Others
13.4 EU-4 and United Kingdom Sarcopenia Market (2017-2032) by Route of Administration
13.4.1 Market Overview
13.4.2 Oral
13.4.3 Parenteral
13.4.4 Others
14 Japan Sarcopenia Market
14.1 Japan Sarcopenia Market Historical Value (2017-2023)
14.2 Japan Sarcopenia Market Forecast Value (2024-2032)
14.3 Japan Sarcopenia Market (2017-2032) by Treatment Type
14.3.1 Market Overview
14.3.2 Protein Supplement
14.3.3 Vitamin B12 Supplement
14.3.4 Vitamin D & Calcium Supplement
14.3.5 Pharmacotherapy
14.3.6 Others
14.4 Japan Sarcopenia Market (2017-2032) by Route of Administration
14.4.1 Market Overview
14.4.2 Oral
14.4.3 Parenteral
14.4.4 Others
15 China Sarcopenia Market
15.1 China Sarcopenia Market (2017-2032) Historical Value (2017-2023)
15.2 China Sarcopenia Market (2017-2032) Forecast Value (2024-2032)
15.3 China Sarcopenia Market (2017-2032) by Treatment Type
15.3.1 Market Overview
15.3.2 Protein Supplement
15.3.3 Vitamin B12 Supplement
15.3.4 Vitamin D & Calcium Supplement
15.3.5 Pharmacotherapy
15.3.6 Others
15.4 China Sarcopenia Market (2017-2032) by Route of Administration
15.4.1 Market Overview
15.4.2 Oral
15.4.3 Parenteral
15.4.4 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Amgen Inc.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisition
22.1.5 Certifications
22.2 F-Hoffmann La-Roche
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisition
22.2.5 Certifications
22.3 American Way (Amway) Corporation
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisition
22.3.5 Certifications
22.4 Abbott laboratories, Inc.
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisition
22.4.5 Certifications
22.5 AbbVie Inc.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisition
22.5.5 Certifications
22.6 Merck Sharp & Dohme Corp.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisition
22.6.5 Certifications
22.7 AstaReal AB
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisition
22.7.5 Certifications
22.8 Pfizer Inc.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisition
22.8.5 Certifications
22.9 Sanofi S.A.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisition
22.9.5 Certifications
22.10 Nestle Health Science
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisition
22.10.5 Certifications
22.11 Zydus Cadila
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisition
22.11.5 Certifications
22.12 Bayer AG
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisition
22.12.5 Certifications
22.13 Amgen Inc.
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisition
22.13.5 Certifications
22.14 Johnson & Johnson.
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisition
22.14.5 Certifications
22.15 Novartis AG
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisition
22.15.5 Certifications
List not exhaustive
23 Sarcopenia Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
*The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 4.3% during the forecast period of 2024-2032, driven by the growing geriatric population across the 8 major markets.
Factors such as rising healthcare expenditure, heightened patient awareness along with research activities to mitigate the impact of sarcopenia on aging patients are fuelling the demand for the market.
One of the significant trends in the market is the development of innovative and effective treatment approaches to address the growing cases of sarcopenia. In July 2023, Biophytis BSA filed for the United States Food and Drug Administration (FDA) approval for SARA-31, the first Phase III study targeting sarcopenia. SARA-31 will evaluate its product Sarconeos' (BIO101) effectiveness and safety in treating sarcopenic patients prone to mobility issues.
The market segmentation by treatment type includes protein supplements, vitamin B12 supplements, vitamin D & calcium supplements, pharmacotherapy, and others.
Based on the route of administration, the market includes oral, parenteral, and others.
Major end users of the market include hospitals, homecare, specialty clinics, and others.
The distribution channels in the market include hospital pharmacies, retail pharmacies, online pharmacies, and others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and China.
Key players involved in the market are Amgen Inc., F-Hoffmann La-Roche, American Way (Amway) Corporation, Abbott Laboratories, Inc., AbbVie Inc., Merck Sharp & Dohme Corp., AstaReal AB, Pfizer Inc., Sanofi S.A., Nestle Health Science, Zydus Cadila, Bayer AG, Amgen Inc., Johnson & Johnson., and Novartis AG.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER